Nanostructured Lipid Carriers: An Approach to Oral Delivery of Drugs

Vidya Sabale; Manasi Jiwankar

doi:10.52711/0974-360X.2024.00380

Research Journal of Pharmacy and Technology

ISSN

0974-360X (Online)
0974-3618 (Print)

Submit Article

Nanostructured Lipid Carriers: An Approach to Oral Delivery of Drugs

Author(s): Vidya Sabale, Manasi Jiwankar

Email(s): mmdnikam@gmail.com

DOI: 10.52711/0974-360X.2024.00380

Address: Vidya Sabale, Manasi Jiwankar*
Department of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, Maharashtra, India.
*Corresponding Author

Published In: Volume - 17, Issue - 5, Year - 2024

View HTML

Purchase PDF

ABSTRACT:
ABSTRACT: The oral route is widely used route of administration as it is safe and convenient. Nanostructured lipid carriers (NLCs) are made of liquid, solid, and surfactant lipids. More drug loading is possible because of the imperfect structure of the lipid matrix in nanostructured lipid carriers.NLCs are biocompatible, biodegradable and show good encapsulation efficiency.They are considered promising nanocarriers for oral delivery. NLCs have been demonstrated to increase the oral bioavailability of hydrophobic pharmaceuticals. They also circumvent hepatic metabolism and impede drug efflux via the P-glycoprotein. This review focuses on the importance of NLCs in drug administration via the oral route, as well as the many hurdles that must be overcome.

Keywords:

Cite this article:
Vidya Sabale, Manasi Jiwankar. Nanostructured Lipid Carriers: An Approach to Oral Delivery of Drugs. Research Journal of Pharmacy and Technology. 2024; 17(5):2427-0. doi: 10.52711/0974-360X.2024.00380

Cite(Electronic):
Vidya Sabale, Manasi Jiwankar. Nanostructured Lipid Carriers: An Approach to Oral Delivery of Drugs. Research Journal of Pharmacy and Technology. 2024; 17(5):2427-0. doi: 10.52711/0974-360X.2024.00380 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-5-76

REFERENCES:
1.   Jeganath S, Asha D, Sathesh S, Keerthi SN, Senthilkumaran K. Oral Controlled Drug Delivery System-A Review. Research Journal of Pharmacy and Technology. 2018; 11: 797-804.
2.   Sao R, Vaish R, Sinha N. Multifunctional Drug Delivery Systems Using Inorganic Nanomaterials: A Review. J Nanoscience and Nanotechnology. 2015;15: 1960–72.
3.   Plapied L, Duhem N, desRieux A, Préat V. Fate of Polymeric Nanocarriers for Oral Drug Delivery. Current Opinion in Colloid Interface Science. 2011; 16: 228–37.
4.   Thulasi R, Subhashis Debnath, Niranjan M, Chakradhar N. A Review on Solid Lipid Nanoparticles. Research Journal of Pharmacy and Technology.2012; 5:1359-68
5.   Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting. Recent Patents on Nanotechnology. 2013; 7: 41–55.
6.   Naga S, Amit P, Gowda A. A Review on Methods of Preparation and Characterizationof the Solid Lipid Nanoparticles. 2020; 13:3433-41.
7.   Souto EB, Doktorovova S. Chapter 6 – Solid Lipid Nanoparticle Formulations Pharmacokinetic and Biopharmaceutical Aspects in Drug Delivery. Methods in Enzymology. 2009;464: 105–29.
8.   Das S, A. Chaudhury A. Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery. AAPS Pharm Sci Tech. 2011;12: 62–76.
9.   Amol D. Solid Lipid Nanoparticles. Research Journal of Pharmaceutical Dosage Forms and Technology. 2014; 6:282-5.
10.   Bakthavachalam A, Remya PN, Damodharan. Review on Solid Lipid Nanoparticles. Research Journal of Pharmacy and Technology. 2020; 13: 4430-4.
11.   Trilochan S, Prasanna P. Solid Lipid Nanoparticles: A Novel Carrier in Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2013;5:56-61.
12.   Akshat S, Amit D, Reenu Y. Solid Lipid Nanoparticles: A promising Nanotechnology. Research Journal of Pharmaceutical Dosage Forms and Technology. 2011;3:167-75.
13.   Müller RH, Radtke M, Wissing SA. Nanostructured Lipid Matrices for Improved Microencapsulation of Drugs. International Journal of Pharmaceutics. 2002; 242: 121-8.
14.   Anupama s, Malay D, Tapash C, Sanjoy D. Nanostructured Lipid Carriers (NLCs) –based Intranasal Drug Delivery System of Tenofovir Disoproxil Fumerate (TDF) for Brain Targeting. Research Journal of Pharmacy and Technology. 2020;13: 5411-24.
15.   Davda J, Labhasetwar V. Characterization of Nanoparticle Uptake by Endothelial Cells. International Journal of Pharmacy. 2002; 233:51–9.
16.   Namdev N, Upadhyay S. Challenges and Aproaches for Oral Protein and Peptide Drug Delivery.Research Journal of Pharmacy and Technology. 2016; 9: 305-12.
17.   Pankaj J, Adhikrao Y. Polymeric Nanosuspension Loaded Oral Thin Films of Flubiprofen: Design, Development and In Vitro Evaluation. Res. J. of Pharm. and Technology. 2020;13: 1905-10.
18.   Knipe JM, Chen F, Peppas NA. Enzymatic Biodegradation of Hydrogels for Protein Delivery Targeted to the Small Intestine. Biomacromolecules. 2015; 16: 962–72.
19.   Bernkop-Schnurch A. Nanocarrier Systems for Oral Drug Delivery: Do We Really Need Them? European Journal of Pharmaceutical Sciences. 2013; 49: 272–7.
20.   Singh R, Lillard JW. Past, Present, and Future Technologies for Oral Delivery of Herapeutic Proteins. Journal of Pharmaceutical Sciences. 2008;97: 2497–23.
21.   Homayun B, Lin X, Choi HJ. Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics. 2019;11: 1-29.
22.   Moreno MR, Qi P, Wong YS, Xiong MG, Zhang Y, Venkatraman S. Polymeric nanomaterials: methods of preparation and characterization. In Nanocarriers for drug delivery, Edited by Mohapatra S, Ranjan S, Dasgupta N, Mishra R, Thomas S.Elsevier,USA. 2019. pp. 557–653.
23.   Brown TD, Whitehead KA, Mitragotri S. Materials for Oral Delivery of Proteins and Peptides. Nature Reviews Materials. 2020;5: 127–48.
24.   Nilesh K, Puja W, Pratiksha S, Shashikant D. A Systematic Review on Oral Drug Delivery as a Fast Dissolving Film to Improve Therapeutic Effectiveness. Res. J. of Pharm. and Tech. 2021; 14: 1771-78.
25.   Poovi G, Damodharan N. Lipid Nanoparticles: A Challenging Approach for Oral Delivery of BCS Class-II Drugs. Future Journal of Pharmaceutical Sciences. 2018; 4:191–05.
26.   Andrysek T. Impact of Physical Properties of Formulations on Bioavailability of Active Substance: Current and Novel Drugs with Cyclosporine. Molecular Immunology. 2003; 39:1061–5.
27.   Andrysek T. Excipients and their Role in Absorption: Influencing Bioavailability of Cyclosporine by Triglycerides and Polyglycerol Esters. Biomedical Papers of the Medical Faculty of University Palacky Olomouc Czech Republic. 2006; 150:227–33.
28.   Hu X, Fan W, Yu Z. Evidence does not Support Absorption of Intact Solid Lipid Nanoparticles via Oral Delivery. Nanoscale. 2016;8:7024–35.
29.   Rizwanullah M, Amin S, Ahmed J. Improved Pharmacokinetics and Antihyperlipidemic Eﬃcacy of Rosuvastatin Loaded Nanostructured Lipid Carriers. Journal of Drug Targeting. 2017 ;25: 58–78.
30.   Jaiswal P, Gidwani B, Vyas A. Nanostructured Lipid Carriers and their Current Application in Targeted Drug Delivery. Artificial Cells Nanomedice and Biotechnology. 2016;44: 27-40.
31.   Han HK, Lee BJ, Lee HK. Enhanced Dissolution and Bioavailability of Biochanina via the Preparation of Solid Dispersion: In vitro and In Vivo Evaluation. International Journal of Pharmaceutics. 2011; 415:89–94.
32.   Luan J, Zheng F, Yang X. Nanostructured Lipid Carriers for Oral Delivery of Baicalin: In Vitro and In Vivo Evaluation. Colloids and Surfaces A Physicochemical and   Engineering Aspects. 2015;466, 154–9.
33.   Khoo SM, Shackleford DM, Porter CJ, Edwards GA, Charman WN. Intestinal Lymphatic Transport of Halofantrine Occurs after Oral Administration of a Unit-dose Lipid-based Formulation to Fasted Dogs. Pharmaceutical Research. 2003; 20: 1460–65.
34.   Lin JH, Yamazaki M. Role of P-glycoprotein in Pharmacokinetics: Clinical Implications. Clinical Pharmacokinetics. 2003; 42: 59–98.
35.   Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH. Efficacy of Novel P-glycoprotein Inhibitors to Increase the Oral Uptake of Paclitaxel in Mice. Investigational New Drugs. 2004;22: 219-29.
36.   Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK. Reversal of Multidrug Resistance by Surfactants. British Journal of Cancer. 1992;66: 62-8.
37.   Tiwari R, K. Pathak K. Nanostructured Lipid Carrier versus Solid Lipid Nanoparticles of Simvastatin: Comparative Analysis of Characteristics, Pharmacokinetics and Tissue Uptake. International Journal of Pharmaceutics. 2011; 415:232-43.
38.   Shete H, Chatterjee S, De A. Long Chain Lipid Based Tamoxifen NLC. Part II: Pharmacokinetic, Biodistribution and In Vitro Anticancer Efficacy Studies. International Journal of Pharmaceutics. 2013; 454:584–92.
39.   ParhiR,Suresh P. Production of Solid Lipid Nanoparticles-drug Loading and Release Mechanism. Journal of Chemical and Pharmaceutical Research. 2010; 2:211-27.
40.   Kreuter J. Peroral Administration of Nanoparticles. Advanced Drug Delivery Reviews. 1991;7: 71-86.
41.   Manjunath K, Venkateswarlu V. Pharmacokinetics, Tissue Distribution and Bioavailability of Clozapine Solid Lipid Nanoparticles after Intravenous and Intraduodenal Administration. Journal of Controlled Release. 2005; 107: 215-28.
42.   Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 Increases Permeability of a Broad Spectrum of Drugs in Polarized Bbmec and Caco-2 Cell Monolayers. Pharmaceutical Research. 1999;16:1366-72.
43.   Trevaskis NL, Charman WN, Porter CJ. Lipid-based Delivery Systems and Intestinal Lymphatic Drug Transport: A Mechanistic Update. Advanced Drug Delivery Reviews. 2008;60: 702-16.
44.   Cense HA, Eijck CH, Tilanus HW. New Insights in the Lymphatic Spread of Oesophageal Cancer and its Implications for the Extent of Surgical Resection. Best Practice and Research: Clinical Gastroenterology. 2006; 20:893-06.
45.   Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR. The Metastatic Cascade in Prostate Cancer. Surgical Oncology. 2006; 15:117-28.